For the 19th prioritisation (May 2014), 11 were filtered out of 149 identified drugs and were sent to prioritisation. Of these, 6 drugs were ranked as ‘highly relevant’ by the expert panel, 3 as ‘relevant’ and 2 as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.